SILVER SPRING, USA (Reuters) – A panel of advisers said
that heart for new studies should require
drugs against obesity, possibly adding a new
obstacle in the way of its adoption.
The food and drug administration panel of
United States ( FDA) voted 17 to 6 that regulators should
forcing companies to conduct studies of heart impact
to sell their drugs in United States, even if the
clinical trials do not show initially evidence of risk
heart.
However, the panel did not discuss even if the evidence
should be out before or after approval.
The news could affect Arena Pharmaceuticals Vivus Inc.
Inc and Orexigen Therapeutics Inc, which are competing for
bring the first drug against obesity to market more of
a decade.